The Treatment Burden of Myopic Choroidal Neovascularization
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorPoliclinico Gaspare Rodolico - San Marco Catania
About this trial
Pathologic myopia (PM) is characterized by progressive eye elongation associated with degenerative changes in the retinal and choroidal tissue. Myopic choroidal neovascularization (mCNV) is a well-known complication of PM, occurring in 5-11% of cases and representing a main cause of visual impairment in working people under the age of 50.
The management of patients affected by active mCNV have been revolutionized by the advent of intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) drugs.
Patients affected by mCNV needs intravitreal injections and visits to assess the need of retreatment with assiduity. It represents a significant burden for patients, caregivers as well as medical equipe.
The aim of this study is to investigate the factors associated with the number of anti-VEGF injections and hospital visits necessary to get mCNV disease stabilization and to identify predictive factors of treatment burden.
Eligibility criteria
Qualifiers
axial length>26 mm or refractive error (spherical equivalent) <-6 Diopters
clinical changes typical of Pathologic myopia
diagnosis of subfoveal or juxtafoveal treatment-naïve myopic choroidal neovascularization (mCNV)
only one eye per patient was included in the analysis, in cases of patients treated bilaterally only the first eye treated was included
Disqualifiers
Extrafoveal mCNV location
Other retinal diseases
any inflammatory condition which may cause CNV including multifocal choroiditis, puntate inner choroidopathy and white dot syndrome
previous ocular surgery (except for cataract extraction performed before the baseline visit)
Trial design
Treatments tested in this trial
- anti-VEGF intravitreal treatment in patients affected by myopic choroidal neovascularization
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov